Yuezong Bai

2.3k total citations · 1 hit paper
60 papers, 987 citations indexed

About

Yuezong Bai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yuezong Bai has authored 60 papers receiving a total of 987 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 32 papers in Cancer Research. Recurrent topics in Yuezong Bai's work include Cancer Genomics and Diagnostics (26 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Genetic factors in colorectal cancer (16 papers). Yuezong Bai is often cited by papers focused on Cancer Genomics and Diagnostics (26 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Genetic factors in colorectal cancer (16 papers). Yuezong Bai collaborates with scholars based in China, Ethiopia and United States. Yuezong Bai's co-authors include Xiaochen Zhao, Mengli Huang, Shangli Cai, Longgang Cui, Shiqing Chen, Jing Zhao, Zhengyi Zhao, Yuzi Zhang, Chan Gao and Zhenghang Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Yuezong Bai

55 papers receiving 980 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

2019 249 citations Longgang Cui, Xiaochen Zhao et al. profile →

Peers

Yuezong Bai

ONCOL

PRM

IMMUN

Hui‐Lan Rao China

Bum Jun Kim South Korea

Deepti Aurora-Garg United States

Zishuo I. Hu United States

Marie Alt France

Xinmin Yu China

Anne‐Laure Pointet France

Bjarne R. Bartlett United States

Jinpeng Shi China

Chen-Yuan Lin Taiwan

Hui‐Lan Rao China

Yuezong Bai

664 ×1.1

ONCOL

218 ×0.5

PRM

142 ×0.5

259 ×1.0

222 ×1.4

IMMUN

Citations per year, relative to Yuezong Bai Yuezong Bai (= 1×) peers Hui‐Lan Rao

Countries citing papers authored by Yuezong Bai

Since Specialization

Citations

This map shows the geographic impact of Yuezong Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuezong Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuezong Bai more than expected).

Fields of papers citing papers by Yuezong Bai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuezong Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuezong Bai. The network helps show where Yuezong Bai may publish in the future.

Co-authorship network of co-authors of Yuezong Bai

This figure shows the co-authorship network connecting the top 25 collaborators of Yuezong Bai. A scholar is included among the top collaborators of Yuezong Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuezong Bai. Yuezong Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yan, Kai, Ding Zhang, Yanan Chen, et al.. (2023). Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Frontiers in Immunology. 14. 1116057–1116057. 3 indexed citations

Qi, Changsong, Yuezong Bai, Hui Chen, et al.. (2023). China special issue on gastrointestinal tumors—NTRK fusion in a large real‐world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment. International Journal of Cancer. 153(11). 1916–1927. 2 indexed citations

Su, Xiaodong, Guangyu Luo, Zhiqiang Wang, et al.. (2023). Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. Journal of Translational Medicine. 21(1). 411–411. 17 indexed citations

Hu, Yajie, Xinya Zhao, Yu Xu, et al.. (2023). An exploration of gastric cancer with heterogeneous mismatch repair status. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 482(3). 517–523. 6 indexed citations

Ju, Wu‐tong, Ronghui Xia, Dongwang Zhu, et al.. (2022). A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nature Communications. 13(1). 78 indexed citations

Wang, Kun, Xuming Wang, Xudong Xiang, et al.. (2022). Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers. Frontiers in Immunology. 13. 811601–811601. 12 indexed citations

Nie, Wei, Zhijie Wang, Kai Zhang, et al.. (2022). ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. BMC Medicine. 20(1). 170–170. 22 indexed citations

Wang, Zhenghang, Xinyu Wang, Yu Xu, et al.. (2022). Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Medicine. 20(1). 133–133. 53 indexed citations

Shen, Wenbin, Boer Shan, Shanhui Liang, et al.. (2021). Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian Cancer. Pathology & Oncology Research. 27. 581534–581534. 7 indexed citations

10.

Li, Pu, Yuezong Bai, Boer Shan, et al.. (2021). Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma. Frontiers in Oncology. 11. 707658–707658. 12 indexed citations

11.

Huang, Jiwei, Wen Cai, Biao Cai, et al.. (2021). Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients. Frontiers in Oncology. 11. 697219–697219. 7 indexed citations

12.

Cheng, Yuan, Cheng Zhang, Shunjun Fu, et al.. (2021). Co-amplification of genes in chromosome 8q24: a robust prognostic marker in hepatocellular carcinoma. Journal of Gastrointestinal Oncology. 12(3). 1086–1100. 3 indexed citations

13.

Zhang, Meng, Changsong Qi, Zhenghang Wang, et al.. (2021). Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. Journal of Molecular Medicine. 99(9). 1311–1321. 7 indexed citations

14.

Xiao, Jian, Wenyun Li, Yan Huang, et al.. (2021). A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer. 21(1). 282–282. 57 indexed citations

15.

Yang, Jing, Xiangyun Wang, Jingli Lü, et al.. (2021). Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations. Journal of Cancer. 12(17). 5099–5105. 11 indexed citations

16.

Wang, Zhenghang, Chang Liu, Yuezong Bai, et al.. (2021). Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Frontiers in Oncology. 11. 761110–761110. 8 indexed citations

17.

Feng, Qi, Xiaojing Du, Zhiying Zhao, et al.. (2021). Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma. Frontiers in Oncology. 11. 729340–729340. 22 indexed citations

18.

Zhou, Taicheng, Zhihua Cai, Ning Ma, et al.. (2020). A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology. 8. 629–629. 59 indexed citations

19.

Li, Junjie, et al.. (2020). Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing. Pathology & Oncology Research. 26(4). 2835–2837. 4 indexed citations

20.

Yang, Jianjun, Guanghui Xu, Jiyang Zheng, et al.. (2020). PD-L1 expression on tumor cells and tumor infiltrating immune cells in Chinese colorectal cancer patients.. Journal of Clinical Oncology. 38(15_suppl). e16111–e16111. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact